An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients

Trial Profile

An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients

Completed
Phase of Trial: Phase II/III

Latest Information Update: 04 Sep 2017

At a glance

  • Drugs Nalbuphine (Primary)
  • Indications Prurigo nodularis
  • Focus Adverse reactions
  • Sponsors Trevi Therapeutics
  • Most Recent Events

    • 20 Jul 2017 Status changed from active, no longer recruiting to completed, according to Trevi Therapeutics media release.
    • 13 Oct 2016 According to Trevi Therapeutics media release, company expects to complete this study in the third quarter of 2017.
    • 26 Sep 2016 Last checked against ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top